Skip to main content
Figure 9 | Cardiovascular Diabetology

Figure 9

From: Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice

Figure 9

Effect of long-term empagliflozin treatment on cognitive function of db/db mice estimated by Morris water maze test. Cognitive function was evaluated by Morris water maze test at 9 weeks after the treatment. (A) indicates escape latency of the hidden platform test on 4 consecutive days (1-20 sessions). (B) indicates number of times across the platform in the probe test. (C) indicates escape latency in the visible test. (D) indicates swimming speeds. Abbreviations used are the same as in Figure 5. Values are mean ± SEM (n = 9-11).

Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840